Global use of Haemophilus influenzae type b conjugate vaccine

Linda R. Ojo; Rosalyn E. O'Loughlin; Adam L. Cohen; Jennifer D. Loo; Karen M. Edmond; Sharmila S. Shetty; Allyson P. Bear; Lois Privor-Dumm; Ulla K. Griffiths; Rana Hajjeh

doi:10.1016/j.vaccine.2010.07.074

Global use of Haemophilus influenzae type b conjugate vaccine

Linda R. Ojo, Rosalyn E. O'Loughlin, Adam L. Cohen, Jennifer D. Loo, Karen M. Edmond, Sharmila S. Shetty, Allyson P. Bear, Lois Privor-Dumm, Ulla K. Griffiths, Rana Hajjeh

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].

Original language	English (US)
Pages (from-to)	7117-7122
Number of pages	6
Journal	Vaccine
Volume	28
Issue number	43
DOIs	https://doi.org/10.1016/j.vaccine.2010.07.074
State	Published - Oct 8 2010

Keywords

Developing countries
Haemophilus influenzae type b
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.07.074

Cite this

@article{6aa19758b9d04dc6a9335e0b9bfb9dc7,

title = "Global use of Haemophilus influenzae type b conjugate vaccine",

abstract = "Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].",

keywords = "Developing countries, Haemophilus influenzae type b, Vaccine",

author = "Ojo, {Linda R.} and O'Loughlin, {Rosalyn E.} and Cohen, {Adam L.} and Loo, {Jennifer D.} and Edmond, {Karen M.} and Shetty, {Sharmila S.} and Bear, {Allyson P.} and Lois Privor-Dumm and Griffiths, {Ulla K.} and Rana Hajjeh",

year = "2010",

month = oct,

day = "8",

doi = "10.1016/j.vaccine.2010.07.074",

language = "English (US)",

volume = "28",

pages = "7117--7122",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "43",

}

TY - JOUR

T1 - Global use of Haemophilus influenzae type b conjugate vaccine

AU - Ojo, Linda R.

AU - O'Loughlin, Rosalyn E.

AU - Cohen, Adam L.

AU - Loo, Jennifer D.

AU - Edmond, Karen M.

AU - Shetty, Sharmila S.

AU - Bear, Allyson P.

AU - Privor-Dumm, Lois

AU - Griffiths, Ulla K.

AU - Hajjeh, Rana

PY - 2010/10/8

Y1 - 2010/10/8

N2 - Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].

AB - Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].

KW - Developing countries

KW - Haemophilus influenzae type b

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77957346208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957346208&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.07.074

DO - 10.1016/j.vaccine.2010.07.074

M3 - Article

C2 - 20691265

AN - SCOPUS:77957346208

SN - 0264-410X

VL - 28

SP - 7117

EP - 7122

JO - Vaccine

JF - Vaccine

IS - 43

ER -

Global use of Haemophilus influenzae type b conjugate vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this